Compare Inovio Pharmaceuticals Inc (INO) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Williams-Sonoma, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.13 (market cap $112.19M), while Williams-Sonoma, Inc. trades at $241.16 (market cap $28.15B). The key difference: Williams-Sonoma, Inc. is far larger — about 250.9× Inovio Pharmaceuticals Inc's market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Williams-Sonoma, Inc. for 59 Days on average.
| INO | WSM | |
|---|---|---|
Market Cap | $112.19M | $28.15B |
Volume | 3,201,278 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.65 | $251.81 |
52-Week Low | $0.66 | $168.64 |
Typical Hold Time | 43 Days | 59 Days |
Enterprise Value | $83.51M | $28.65B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Williams-Sonoma (WSM) trades at $241.75, up 0.54% on the day, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.10 surpassing the $2.08 expectation. Revenue for 2025 was $7.71 billion, with a robust net income margin of 14.73% and high ROE of 54.96%. Recent news highlights market share gains and profitability improvements, including a new Pottery Barn collaboration and store expansion.
The outlook for WSM is positive, driven by earnings momentum, margin strength, and strategic initiatives. However, risks include competitive pressures in home furnishings and sensitivity to housing market trends. Analyst consensus is a buy with a $246.31 price target, suggesting modest upside from current levels, supported by institutional confidence and dividend declarations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
